Ticagrelor Flow
Research type
Research Study
Full title
Assessment of enhancement of coronary flow by ticagrelor in patients with atherosclerosis and coronary stenoses
IRAS ID
153417
Contact name
Justin Davies
Contact email
Sponsor organisation
Imperial College
Duration of Study in the UK
1 years, 6 months, 1 days
Research summary
Coronary arteries that have atherosclerosis and blockages ('stenoses') have reduced coronary flow which can cause heart attacks and angina chest pains. Patients take medicines to reduce the stickiness of their blood to stop clots forming in their coronary arteries that could cause a heart attack. One such drug, that has been shown in a large randomised study of 18,624 patients, reduces heart attacks and death more than others more commonly used. Clinical guidelines and UK's NICE now recommend this drug for patients with heart attacks.
To understand why this drug is so successful in reducing death, studies have measured flow in the coronary arteries of healthy volunteers and found it is increased when the heart is stressed. We want to test whether this drug increases coronary flow in patients who already have coronary artery blockages and whether this increase is meaningful. We will measure coronary flow in patients before and after they have had the drug to see if their flow has improved. This will help us understand when to use this drug and help others similar to it.
REC name
London - Fulham Research Ethics Committee
REC reference
15/LO/0830
Date of REC Opinion
18 Aug 2015
REC opinion
Further Information Favourable Opinion